The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.
Medpage Today on MSN22h
GLP-1 Receptor Agonists for Diabetes Tied to Slightly Lower Depression RiskAmong 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.
A recently retired U.S. senator is calling on the Arizona legislature to pass a bill to fund clinical trials into ibogaine, ...
The American Heart Association issued a scientific statement highlighting the significance of mental health in maternal CV ...
News Medical on MSN19h
FDA-approved technology offers personalized treatment for Parkinson’s symptomsStarting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.
Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...
Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...
Pharmaceutical Technology on MSN6d
Supernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback